がん診断の世界市場

◆英語タイトル:Cancer Diagnostics Market: Biopsy Test Type Segment Expected to Remain Dominant Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026
◆商品コード:FUMI709018
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2017年5月17日
◆ページ数:207
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual PriceUSD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
Corporate PriceUSD7,500 ⇒換算¥840,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。

Future Market Insightsが発行した本調査レポートでは、がん診断の世界市場について調査・分析し、がん診断の世界市場動向、がん診断の世界市場規模、市場予測、セグメント別がん診断市場分析、地域別市場規模(北米市場、南米市場、アジア市場、日本市場、ヨーロッパ市場など)、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

Biopsy is expected to remain the most lucrative cancer diagnostics test due to technological advancements such as fine needle aspiration
The biopsy test type segment dominated the global cancer diagnostics market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Biopsy is the largest segment, which was valued at more than US$ 11 Bn in 2016 and is expected to expand at a CAGR of 7.4% over the forecast period. The liquid biopsy test type segment is expected to register fastest Y-o-Y growth throughout the forecast period. Even though liquid biopsy is becoming more popular due to its non-invasive nature, to obtain an accurate diagnosis, solid tumour biopsies or tissue biopsies are still preferred.

Despite the headwinds of regulatory uncertainties, diagnostic companies continue to invest in high dollar molecular diagnostic tests for cancer research

To purchase test reagents, a majority of diagnostic companies place these instruments in diagnostic and research laboratories through reagent rental contracts in exchange for long-term contracts, as tests can only be run in laboratories possessing instruments for which the test is developed and approved. Moreover, newly developed tests for particular instruments need to be mass marketed to diagnostic laboratories, general practitioners, and health insurers. For instance, big players such as Roche Diagnostics, Abbott etc. license their cancer test products to regional geographical partners who either distribute these products in the region or develop reagent kits for their instruments. Addressing the huge needs in cancer diagnostics require the participation of established diagnostics industry players.

Changing competition landscape is the new trend that can be seen in the global cancer diagnostics market. Although molecular testing is a hotspot for investment in vitro diagnostic, the market shows delayed growth due to slow returns on investment. In spite of this, all big diagnostic players in the global market are continuously investing in cancer diagnostics including molecular biomarker testing, NGS, PET scanners etc. Companies are also investing in automation of existing molecular assays to foster future growth prospects. The majority of cancer diagnostic players are adopting inorganic growth strategies to sustain the increasing competitive pressure. Companies in the global market are actively engaged in mergers and acquisitions, as the industry is in its growth phase because of continuous technology upgrades and launch of novel blood tests to detect cancer. Key players in the liquid biopsy industry have started taking strategic decisions to engage in mergers and acquisitions to strengthen their product portfolio and increase their brand share in the market.

Change in regulatory policies is reflecting in the change of approach towards cancer diagnostics. Due to automation of laboratory testing methods, traditional methods have been replaced by high-volume models and tests have become commoditised

Regional forecast of the test type segment

The biopsy test type segment dominated the North America cancer diagnostics market in terms of revenue in 2015 and is projected to continue to do so throughout the forecast period. Biopsy is expected to be the most lucrative segment in the North America cancer diagnostics market, with a market attractiveness index of 2.9. Steady advances in the field of bone marrow biopsy in the last few years have facilitated the accurate diagnosis of complex indications such as Hodgkin’s lymphoma, lymphoplasmacytic lymphoma and other cancers of lymph and vascular systems. The biopsy segment is expected to be the most lucrative test type segment in the Western Europe cancer diagnostics market, with a market attractiveness index of 3.2. New developments in fine needle aspiration tools for diagnosis of different cancer indications including lung cancers, head and neck cancers and advanced breast cancer among others has led to an increased demand for tissue biopsy. Further, majority of lung cancers are diagnosed at a late stage where fine needle aspiration biopsy is the only possible test done to confirm the presence of cancer.

【レポートの目次】

Table Of Content

1.Executive Summary

2. Market Introduction

2.1.Market Definition

2.2. Market Taxonomy

3. Global Cancer Diagnostics Market Analysis Scenario

3.1.Market Size (US$ Mn) and Forecast

3.1.1.Market Size and Y-o-Y Growth

3.1.2.Absolute $ Opportunity

4. Market Dynamics

4.1.Macro-economic Factors

4.2. Drivers

4.2.1.Supply Side

4.2.2.Demand Side

4.3.Restraints

4.4.Opportunity

4.5.Forecast Factors – Relevance and Impact

4.6.Key Industry Developments

4.7.Cancer Epidemiology, By Region

4.8.Cancer Diagnostics Regulatory and Reimbursement Scenario

4.9.Porter’s Analysis

4.10.Next-generation Sequencing: A Breakthrough in Cancer Diagnostics

5.Global Cancer Diagnostics Market Analysis and Forecasts, By Test Type

5.1.Introduction

5.2.Basis Point Share (BPS) Analysis By Test Type

5.3.Y-o-Y Growth Projections By Test Type

5.4.Market Value Forecast By Test, 2016–2026

5.4.1. Tumor Biomarkers Tests

5.4.1.1.PSA Tests

5.4.1.2.CTC Tests

5.4.1.3.AFP Tests

5.4.1.4.CA-19 Tests

5.4.1.5.HER2 Tests

5.4.1.6.BRCA Tests

5.4.1.7.ALK Tests

5.4.1.8.CEA Tests

5.4.1.9.EGFR Mutation Tests

5.4.1.10.KRAS Mutation Tests

5.4.1.11.Others

5.4.2.Imaging

5.4.2.1.Ultrasound

5.4.2.2.Mammography

5.4.2.3.MRI Scan

5.4.2.4.PET Scan

5.4.2.5.CT Scan

5.4.2.6.SPECT & Others

5.4.3.Biopsy

5.4.3.1.Needle Biopsy

5.4.3.2.Endoscopic Biopsy

5.4.3.3.Bone Marrow Biopsy

5.4.3.4.Others

5.4.4.Liquid Biopsy

5.4.5.Immunohistochemistry

5.4.6.In Situ Hybridization

5.5.Market Attractiveness Analysis By Test Type

6.Global Cancer Diagnostics Market Analysis and Forecasts, By End User

6.1.Introduction

6.2.Basis Point Share (BPS) Analysis By End User

6.3.Y-o-Y Growth Projections By End User

6.4.Market Value Forecast By End User, 2016–2026

6.4.1.Hospital Associated Labs

6.4.2.Independent Diagnostic Laboratories

6.4.3.Diagnostic Imaging Centers

6.4.4.Cancer Research Institutes

6.4.5.Others

6.5.Market Attractiveness Analysis By End User

7.Global Cancer Diagnostics Market Analysis and Forecasts, By Indication

7.1.Introduction

7.2.Basis Point Share (BPS) Analysis By Indication

7.3.Y-o-Y Growth Projections By Indication

7.4.Market Value Forecast By Indication, 2016–2026

7.4.1.Breast Cancer

7.4.2.Lung Cancer

7.4.3.Colorectal Cancer

7.4.4.Melanoma

7.4.5.Blood Cancers

7.4.6.Prostate Cancer

7.4.7.Ovarian Cancer

7.4.8.Stomach Cancer

7.4.9.Liver Cancer

7.4.10.Others

7.5.Market Attractiveness Analysis By Indication

8.Global Cancer Diagnostics Market Analysis and Forecasts, By Region

8.1.Basis Point Share (BPS) Analysis By Region

8.2.Y-o-Y Growth Projections By Region

8.3.Market Value Forecast By Region

8.3.1.North America

8.3.2.Latin America

8.3.3.Western Europe

8.3.4.Eastern Europe

8.3.5.APEJ

8.3.6.Japan

8.3.7.MEA

8.4.Market Attractiveness Analysis By Region

9.North America Cancer Diagnostics Market Analysis and Forecast

9.1.Introduction

9.1.1.Basis Point Share (BPS) Analysis By Country

9.1.2.Y-o-Y Growth Projections By Country

9.2.Market Value Forecast By Test, 2016–2026

9.2.1.Tumor Biomarkers Tests

9.2.1.1.PSA Tests

9.2.1.2.CTC Tests

9.2.1.3.AFP Tests

9.2.1.4.CA-19 Tests

9.2.1.5.HER2 Tests

9.2.1.6.BRCA Tests

9.2.1.7.ALK Tests

9.2.1.8.CEA Tests

9.2.1.9.EGFR Mutation Tests

9.2.1.10.KRAS Mutation Tests

9.2.1.11.Others

9.2.2.Imaging

9.2.2.1.Ultrasound

9.2.2.2.Mammography

9.2.2.3.MRI Scan

9.2.2.4.PET Scan

9.2.2.5.CT Scan

9.2.2.6.SPECT & Others

9.2.3.Biopsy

9.2.3.1.Needle Biopsy

9.2.3.2.Endoscopic Biopsy

9.2.3.3.Bone Marrow Biopsy

9.2.3.4.Others

9.2.4.Liquid Biopsy

9.2.5.Immunohistochemistry

9.2.6.In Situ Hybridization



【レポートのキーワード】

がん診断

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん診断の世界市場(Cancer Diagnostics Market: Biopsy Test Type Segment Expected to Remain Dominant Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆